- Adding anlotinib in gradual or local progression on first-line EGFR-TKIs for advanced non-small cell lung cancer: A single-arm, multicenter, phase II trialChen, H.; Hu, Y.; Fan, Y.; Wu, G.; Cang, S.; Yang, Y.; Yang, N.; Ma, R.; Jing, G.; Liu, A.; Xu, X.; Tang, S.; Cheng, Y.; Yu, Y.; Wu, Y-L.
- Furmonertinib versus gefitinib in treatment-naive EGFR mutated non-small cell lung cancer: A randomized, double-blind, multi-center, phase III study (FURLONG)Shi, Y-K.; Chen, G.; Wang, X.; Liu, Y.; Wu, L.; Hao, Y.; Liu, C.; Zhu, S.; Zhang, X.; Li, Y.; Liu, J.; Cao, L.; Cheng, Y.; Zhao, H.; Zhang, S.; Zang, A.; Cui, J.; Feng, J.; Liu, F.; Gu, C.被引 3
- Patient-reported outcomes of furmonertinib versus gefitinib in patients with locally advanced or metastatic, EGFR mutation-positive non-small cell lung cancer (FURLONG): A multicenter, double-blind, randomized phase 3 studyShi, Yuankai; Chen, Gongyan; Wang, Xiang; Liu, Yunpeng; Wu, Lin; Hao, Yanrong; Liu, Chunling; Zhu, Shuyang; Zhang, Xiaodong; Li, Yuping; Liu, Jiwei; Cao, Lejie; Cheng, Ying; Zhao, Hui; Zhang, Shucai; Zang, Ai-min; Cui, Jiuwei; Feng, Jian; Yang, Nong; Hu, JieAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL, 2023-06-02 To 2023-06-06.
会议论文
A multicenter, randomized, double-blind, phase III study of gefitinib in combination with anlotinib or placebo in previously untreated patients with EGFR mutation-positive advanced non-small cell lung cancer (FL-ALTER)
16阅读
